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1. INTRODUCTION {#mgg31126-sec-0005}
===============

High‐grade pulmonary neuroendocrine neoplasms (NENs), small‐cell lung cancer (SCLC), and large‐cell neuroendocrine carcinoma of the lung (LCNEC) are among the malignancies with the highest mortality rates. Since the revised 2015 World Health Organization classification of lung tumors classified LCNEC as a NEN (Travis, Brambilla, Burke, Marx, & Nicholson, [2015](#mgg31126-bib-0102){ref-type="ref"}), debates and investigations of the new classification were ceaseless. LCNEC was grouped with NENs due to its similarities with SCLC in terms of morphology, DNA methylation, protein levels, mutational aspects, and transcriptional levels (Aly et al., [2019](#mgg31126-bib-0002){ref-type="ref"}; Karlsson et al., [2015](#mgg31126-bib-0048){ref-type="ref"}, [2014](#mgg31126-bib-0049){ref-type="ref"}; Miyoshi et al., [2017](#mgg31126-bib-0078){ref-type="ref"}; Rossi et al., [2005](#mgg31126-bib-0089){ref-type="ref"}; Simbolo et al., [2017](#mgg31126-bib-0095){ref-type="ref"}), in spite of a certain extent of heterogeneity (Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM), [2013](#mgg31126-bib-0020){ref-type="ref"}; Rossi et al., [2005](#mgg31126-bib-0089){ref-type="ref"}; Simbolo et al., [2017](#mgg31126-bib-0095){ref-type="ref"}). In addition, despite the differences in histopathological characteristics between SCLC and LCNEC, their clinical characteristics are similar, including a generally poor outcome, greater incidence in men than in women, and advanced stage diagnosis (Asamura et al., [2006](#mgg31126-bib-0004){ref-type="ref"}; Cerilli, Ritter, Mills, & Wick, [2001](#mgg31126-bib-0010){ref-type="ref"}; Xu et al., [2019](#mgg31126-bib-0127){ref-type="ref"}). With regard to treatment, individuals with SCLC and LCNEC may manifest different sensitivities to different types of treatment, owing to gene alterations between SCLC‐like LCNEC and NSCLC‐like LCNEC (Rekhtman et al., [2016](#mgg31126-bib-0088){ref-type="ref"}).

Genome‐based medicine, which has been used in oncology for \>10 years, can rapidly detect differentially expressed genes and provide greater chances of reducing malignancy‐related morbidity and mortality (Vogelstein et al., [2013](#mgg31126-bib-0107){ref-type="ref"}). Therefore, a number of valuable clues obtained from the SCLC regulation and LCNEC development could be investigated from different perspectives using gene chips. However, the understanding of the genetic expression of these two types of NEN is limited. Genetic analysis was therefore conducted to clarify the genomic characteristics of NENs and determine the similarities between SCLC and LCNEC, consequently identifying more potential genetic candidates for treatment.

In this study, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1037> expression microarray data were downloaded from the Gene Expression Omnibus (GEO) database. DEGs were analyzed and their interaction patterns in this dataset were revealed through a protein--protein interaction (PPI) network. In addition, possible DEG functions were explored by gene and biological pathway enrichment analysis. The functions of the significant genes involved in major function terms were discussed, and a number of them might be novel candidates for SCLC and LCNEC treatment. The workflow of the present study is depicted in Figure [1](#mgg31126-fig-0001){ref-type="fig"} (free images were obtained from Servier Medical Art).

![Workflow for identification of hub genes and pathways in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung. Step 1: We identified the differentially expressed genes commonly in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung. Step 2: The GO and biological pathway analysis were performed and the PPI network was constructed. Next, we identified the hub genes from the PPI network. Step 3: We validated expression patterns and re‐analysis biological pathway of hub genes. Then, the target miRNAs associated with hub genes were identified and gene‐miRNA networks were constructed. Free images were obtained from Servier Medical Art](MGG3-8-e1126-g001){#mgg31126-fig-0001}

2. MATERIALS AND METHODS {#mgg31126-sec-0006}
========================

2.1. Ethical compliance {#mgg31126-sec-0007}
-----------------------

This article does not contain any studies with human participants or animals performed by any of the authors, and therefore no ethical compliance is required.

2.2. Gene expression profile data {#mgg31126-sec-0008}
---------------------------------

Gene expression profiles (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1037>) were obtained from the GEO database, based on the GPL962 CHUGAI 41K platform. Data including 18 primary normal lung tissues, 8 primary LCNEC tissues, 15 primary small‐cell lung carcinoma tissues, and 9 small‐cell lung carcinoma cell lines were downloaded. The profiles of differentially expressed genes in SCLC and LCNEC are presented in a volcano plot online <http://www.ehbio.com/ImageGP/>.

2.3. Data processing of DEGs {#mgg31126-sec-0009}
----------------------------

The mRNA expression raw data were analyzed by GEO2R online tools (Davis & Meltzer, [2007](#mgg31126-bib-0021){ref-type="ref"}). To identify DEGs in SCLC and LCNEC, as compared with normal lung specimens, \|logFC\| \> 2 and adjusted *p* \< .05 were used as the threshold. A Venn diagram was drawn to visualize shared genes in SCLC and LCNEC specimens.

2.4. Functional enrichment analysis of DEGs {#mgg31126-sec-0010}
-------------------------------------------

Annotation, Visualization and Integrated Discovery (DAVID) (Huang da, Sherman, & Lempicki, [2009a](#mgg31126-bib-0042){ref-type="ref"}, [2009b](#mgg31126-bib-0043){ref-type="ref"}), a bioinformatics online tool, provides functional annotations and gene analysis. Purpose genes were integrated using Gene ontology (GO) analysis in DAVID, to identify their biological properties. Biological pathway analysis of DEGs and hub genes was performed using FunRich software (Pathan et al., [2017](#mgg31126-bib-0086){ref-type="ref"}), a self‐contained software tool used for function enrichment and interaction network evaluation of sets of genes and proteins.

2.5. PPI network construction and module analysis {#mgg31126-sec-0011}
-------------------------------------------------

Search Tool for the Retrieval of Interacting Genes (STRING) (Szklarczyk et al., [2015](#mgg31126-bib-0099){ref-type="ref"})) is a database of known and potential PPIs. DEGs were evaluated by STRING and a combined score of ≥0.4 was set as the cut‐off value. The network was visualized by Cytoscape (Shannon et al., [2003](#mgg31126-bib-0093){ref-type="ref"}) and the Cytoscape app Molecular Complex Detection (MCODE) was then used to examine marked modules of the PPI network, with the advanced option set to a max. depth of 100, degree cut‐off of 2, k‐core of 2, and node score cut‐off of 0.2.

2.6. Oncomine analysis {#mgg31126-sec-0012}
----------------------

To validate the hub genes, the Oncomine website (<http://www.oncomine.org>) was used to obtain mRNA expression data to compare SCLC and normal lung tissues from Bhattacharjee et al. ([2001](#mgg31126-bib-0006){ref-type="ref"}) and Garber et al. ([2001](#mgg31126-bib-0027){ref-type="ref"}).

2.7. Prediction of target miRNAs for DEGs {#mgg31126-sec-0013}
-----------------------------------------

To detect predicted miRNAs corresponding to core genes selected from MCODE, miRNA enrichment in FunRich software was performed and miRNAs found to interact with hub genes were defined. The results were input into and visualized by Cytoscape.

2.8. Statistical analysis {#mgg31126-sec-0014}
-------------------------

In this study, a student\'s *t*‐test was carried out using GraghPad Prism 5 to generate a *p*‐value for the comparison of cancerous specimens and normal control samples. *p* \< .05 was considered to indicate a statistically significant difference.

3. RESULTS {#mgg31126-sec-0015}
==========

3.1. Identification of DEGs {#mgg31126-sec-0016}
---------------------------

DEGs in the SCLC and LCNEC samples, as compared with normal ones, were determined using GEO2R online analyzer (\|logFC\| \> 2 and adjusted *p* \< .05) (Davis & Meltzer, [2007](#mgg31126-bib-0021){ref-type="ref"}). A total of 270 and 114 DEGs were extracted from SCLC and LCNEC samples, respectively. A "volcano plot" between *p*‐values and fold changes was established to plot the differentially expressed genes (Figure [2](#mgg31126-fig-0002){ref-type="fig"}). A Venn diagram was then drawn to confirm the shared DEGs in the two subtypes (Figure [3](#mgg31126-fig-0003){ref-type="fig"}). Finally, 88 common DEGs were confirmed, including 56 downregulated and 32 upregulated genes in the SCLC and LCNEC samples (Table [1](#mgg31126-tbl-0001){ref-type="table"}).

![Volcano plot of the DEGs. (a) Volcano plot for the DEGs in small cell lung carcinoma, as compared with normal lung samples. (b) Volcano plot for the DEGs in large cell neuroendocrine carcinoma of the lung, as compared with normal lung samples. The x‐axis demonstrates the log 2 fold change, and the y‐axis demonstrates the log10 (adjusted *p*‐value). The red dots indicate up‐regulated genes, and the green dots indicate down‐regulated genes. The DEGs were filtered on the basis of a \|log 2 fold change\|\> 1.0 and an adjusted *p*‐value of \< .05. The grey dots represent genes with no significant difference. DEGs, differentially expressed genes](MGG3-8-e1126-g002){#mgg31126-fig-0002}

![Identification of 88 common DEGs in two types of NENs (SCLC and LCNEC) via Venn diagrams. (a) 32 DEGs are upregulated in the two types of NENs (logFC \> 0). (b) 56 DEGs are downregulated in the two types of NENs (logFC \< 0). Different color meant different types. SClC, small cell lung carcinoma. LCNEC, large cell neuroendocrine carcinoma of the lung](MGG3-8-e1126-g003){#mgg31126-fig-0003}

###### 

Commonly DEGs in the SCLC and LCNEC samples

  DEGs            Genes name
  --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated     ZNF829 BCCIP PTTG1 CENPA FAM123A SESN2 CSE1L LOC256676///CDCA5 PBK UBE2TC5orf13 ZNF587 UNQ353///CSNK1G1///KIAA0101 HMGB3 SOX4 FARP1 C1orf215///STMN1 MLF1IP AURKA MYBL2 ZWINTAS///ZWINT UBE2C EZH2 RFC4 CDCA8 SLC2A1 LOC253012 TPX2 TTKCDCA7 TOP2A NUF2
  Downregulated   ADH1B CAV1 WIF1 SFTPC FMO2 TSHZ2///ADAMTS8 USP42 MFAP4 SCGB1A1 IGSF10 TIMP3 CLDN18 OGN CAV2 MAOA FABP4 ZNF521 SVEP1 EPAS1 TPSB2///TPSAB1 FHL1 FAT4 CAB39L ADH1C PI4KAP1 C2orf34 AGER LOC144571///PZP///A2M AQP4 FAM75A1 SFTPH AQP1 CAMP HBE1 EMCN HNRNPH1 SLC39A8 SUSD2 FLJ44379 LIMCH1 SLPI CYBRD1 HOPX C13orf15 LOC100131277///TACC1 LYVE1 GPR116 MAOB SELENBP1 PGM5 EMP2 PMP22 S1PR1 ABCA8 ANGPTL1 RGS2

Abbreviations: DEGs, differentially expressed genes; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell lung carcinoma.
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3.2. Enrichment analysis {#mgg31126-sec-0017}
------------------------

All 88 DEGs were analyzed using DAVID and FunRich software. The GO analysis results were as follows: (a) For biological processes (BP), the significantly enriched terms of upregulated DEGs were cell division, regulation of transcription, DNA repair, homologous chromosome segregation, positive regulation of exit from mitosis, mitotic nuclear division, glucose import, chromosome organization, protein K11‐linked ubiquitination, mitotic spindle organization and mitotic spindle assembly, and the significant terms of downregulated DEGs were caveola assembly, cell adhesion, receptor‐mediated endocytosis of virus by host cell, dopamine catabolic process, neurotransmitter catabolic process, multicellular organismal water homeostasis, angiogenesis, bleb assembly, ethanol oxidation, glycerol transport, and cellular water homeostasis; (b) for molecular function (MF), the notably enriched terms of upregulated DEGs were ubiquitin protein ligase binding, DNA binding, adenosine triphosphate (ATP) binding, peptidase inhibitor activity and ubiquitin conjugating enzyme activity, and those for downregulated DEGs were oxidoreductase, transporter, alcohol dehydrogenase (zinc‐dependent), water transmembrane transporter, primary amine oxidase, glycerol channel and water channel activities; (c) for GO cell component (CC), the upregulated DEGs were particularly enriched in cytoplasm, nucleus, axon hillock, chromosome passenger complex, nucleoplasm, pronucleus and spindle midzone, and downregulated DEGs in extracellular exosome, plasma membrane, caveola, extracellular region, membrane raft, apical part of cell, integral component of membrane, extracellular matrix, extracellular space, and acrosomal membrane (Table [2](#mgg31126-tbl-0002){ref-type="table"}). These results are displayed in bar graphs produced on GraghPad Prism 5 (Figure [4](#mgg31126-fig-0004){ref-type="fig"}).

###### 

Enriched Go terms of the DEGs

                     Category                                                          Term                           Count         \%            *p*‐Value     FDR
  ------------------ ----------------------------------------------------------------- ------------------------------ ------------- ------------- ------------- -------------
  Up regulated       GOTERM_BP_DIRECT                                                  GO:0051301\~cell division      6             0.142993327   4.04E‐06      0.004971483
  GOTERM_BP_DIRECT   GO:0006355\~regulation of transcription DNA‐templated             7                              0.166825548   3.53E‐04      0.432578524   
  GOTERM_BP_DIRECT   GO:0006281\~DNA repair                                            4                              0.095328885   8.15E‐04      0.997007591   
  GOTERM_BP_DIRECT   GO:0045143\~homologous chromosome segregation                     2                              0.047664442   .006639221    7.86341138    
  GOTERM_BP_DIRECT   GO:0031536\~positive regulation of exit from mitosis              2                              0.047664442   .008292426    9.731016783   
  GOTERM_BP_DIRECT   GO:0007067\~mitotic nuclear division                              3                              0.071496663   .013030094    14.89218414   
  GOTERM_BP_DIRECT   GO:0046323\~glucose import                                        2                              0.047664442   .018156528    20.17047326   
  GOTERM_BP_DIRECT   GO:0051276\~chromosome organization                               2                              0.047664442   .023053317    24.9298377    
  GOTERM_BP_DIRECT   GO:0070979\~protein K11‐linked ubiquitination                     2                              0.047664442   .037603917    37.57710332   
  GOTERM_BP_DIRECT   GO:0007052\~mitotic spindle organization                          2                              0.047664442   .037603917    37.57710332   
  GOTERM_BP_DIRECT   GO:0090307\~mitotic spindle assembly                              2                              0.047664442   .045597774    43.66110836   
  GOTERM_CC_DIRECT   GO:0005737\~cytoplasm                                             15                             0.357483317   2.21E‐05      0.022280174   
  GOTERM_CC_DIRECT   GO:0005634\~nucleus                                               14                             0.333651096   5.40E‐05      0.054460588   
  GOTERM_CC_DIRECT   GO:0043203\~axon hillock                                          2                              0.047664442   .00741693     7.237425098   
  GOTERM_CC_DIRECT   GO:0032133\~chromosome passenger complex                          2                              0.047664442   .00741693     7.237425098   
  GOTERM_CC_DIRECT   GO:0005654\~nucleoplasm                                           7                              0.166825548   .010502317    10.10650713   
  GOTERM_CC_DIRECT   GO:0045120\~pronucleus                                            2                              0.047664442   .013312558    12.64989615   
  GOTERM_CC_DIRECT   GO:0051233\~spindle midzone                                       2                              0.047664442   .022093237    20.18460143   
  GOTERM_MF_DIRECT   GO:0031625\~ubiquitin protein ligase binding                      3                              0.076628352   .011662791    10.93819391   
  GOTERM_MF_DIRECT   GO:0008301\~DNA binding bending                                   2                              0.051085568   .015851015    14.59560577   
  GOTERM_MF_DIRECT   GO:0005524\~ATP binding                                           6                              0.153256705   .027091606    23.75384229   
  GOTERM_MF_DIRECT   GO:0030414\~peptidase inhibitor activity                          2                              0.051085568   .030054212    26.01571812   
  GOTERM_MF_DIRECT   GO:0061631\~ubiquitin conjugating enzyme activity                 2                              0.051085568   .038482685    32.12464677   
  Down regulated     GOTERM_BP_DIRECT                                                  GO:0070836\~caveola assembly   3             0.046260601   6.99E−05      0.098559412
  GOTERM_BP_DIRECT   GO:0007155\~cell adhesion                                         6                              0.092521203   .007419687    9.977332032   
  GOTERM_BP_DIRECT   GO:0019065\~receptor‐mediated endocytosis of virus by host cell   2                              0.030840401   .008018493    10.74080337   
  GOTERM_BP_DIRECT   GO:0042420\~dopamine catabolic process                            2                              0.030840401   .013329193    17.25342044   
  GOTERM_BP_DIRECT   GO:0042135\~neurotransmitter catabolic process                    2                              0.030840401   .021243157    26.14357095   
  GOTERM_BP_DIRECT   GO:0050891\~multicellular organismal water homeostasis            2                              0.030840401   .021243157    26.14357095   
  GOTERM_BP_DIRECT   GO:0001525\~angiogenesis                                          4                              0.061680802   .021777665    26.71078904   
  GOTERM_BP_DIRECT   GO:0032060\~bleb assembly                                         2                              0.030840401   .026484616    31.53390357   
  GOTERM_BP_DIRECT   GO:0006069\~ethanol oxidation                                     2                              0.030840401   .031698626    36.53140253   
  GOTERM_BP_DIRECT   GO:0015793\~glycerol transport                                    2                              0.030840401   .034295382    38.89185575   
  GOTERM_BP_DIRECT   GO:0009992\~cellular water homeostasis                            2                              0.030840401   .034295382    38.89185575   
  GOTERM_CC_DIRECT   GO:0070062\~extracellular exosome                                 16                             0.246723207   .001317986    1.408901211   
  GOTERM_CC_DIRECT   GO:0005886\~plasma membrane                                       19                             0.292983809   .003743762    3.955034143   
  GOTERM_CC_DIRECT   GO:0005901\~caveola                                               3                              0.046260601   .010295194    10.53630766   
  GOTERM_CC_DIRECT   GO:0005576\~extracellular region                                  10                             0.154202005   .01150877     11.70950819   
  GOTERM_CC_DIRECT   GO:0045121\~membrane raft                                         4                              0.061680802   .012603718    12.75603307   
  GOTERM_CC_DIRECT   GO:0045177\~apical part of cell                                   3                              0.046260601   .013532583    13.63498448   
  GOTERM_CC_DIRECT   GO:0016021\~integral component of membrane                        20                             0.308404009   .018955008    18.60768595   
  GOTERM_CC_DIRECT   GO:0031012\~extracellular matrix                                  4                              0.061680802   .032469722    29.89178143   
  GOTERM_CC_DIRECT   GO:0005615\~extracellular space                                   8                              0.123361604   .036771948    33.17391345   
  GOTERM_CC_DIRECT   GO:0002080\~acrosomal membrane                                    2                              0.030840401   .043912815    38.31524409   
  GOTERM_MF_DIRECT   GO:0016491\~oxidoreductase activity                               4                              0.061680802   .014279333    14.99791487   
  GOTERM_MF_DIRECT   GO:0005215\~transporter activity                                  4                              0.061680802   .014662761    15.37073704   
  GOTERM_MF_DIRECT   GO:0004024\~alcohol dehydrogenase activity zinc‐dependent         2                              0.030840401   .015188693    15.87969632   
  GOTERM_MF_DIRECT   GO:0005372\~water transmembrane transporter activity              2                              0.030840401   .015188693    15.87969632   
  GOTERM_MF_DIRECT   GO:0008131\~primary amine oxidase activity                        2                              0.030840401   .015188693    15.87969632   
  GOTERM_MF_DIRECT   GO:0015254\~glycerol channel activity                             2                              0.030840401   .030151975    29.24210187   
  GOTERM_MF_DIRECT   GO:0015250\~water channel activity                                2                              0.030840401   .040003884    36.95130237   

Abbreviations: DEGs, differentially expressed genes; Go, Gene ontology.
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![GO terms of overlapped differentially expressed genes. (a) Up‐regulated genes. (b) Down‐regulated genes. Green bars, biological process; blue bars, cellular component; red bars, molecular function. GO, Gene ontology](MGG3-8-e1126-g004){#mgg31126-fig-0004}

The biological pathway analysis results are shown in Figure [5](#mgg31126-fig-0005){ref-type="fig"}, indicating that upregulated DEGs were notably enriched in cell cycle (mitotic), DNA replication, ataxia telangiectasia‐mutated (ATM) pathway, mitotic M‐M/G1 phases, signaling by Aurora kinases, M phase, mitotic prometaphase, while downregulated DEGs in lipid digestion, mobilization and transport, noradrenaline and adrenaline degradation, and serotonin degradation (Figure [5](#mgg31126-fig-0005){ref-type="fig"}).

![Biological pathway analysis for DEGs. (a) Biological pathways for upregulated DEGs. (b) Biological pathways for downregulated DEGs. DEGs, differentially expressed genes](MGG3-8-e1126-g005){#mgg31126-fig-0005}

3.3. PPI network and module analysis {#mgg31126-sec-0018}
------------------------------------

Using STRING, a PPI network containing 48 nodes and 221 protein pairs was constructed, with a combined score of \>0.4. As shown in Figure [6](#mgg31126-fig-0006){ref-type="fig"}, most nodes in the PPI network were upregulated DEGs in SCLC and LCNEC specimens. Next, the MCODE app in Cytoscape was used for further analysis, which showed that 16 of 48 nodes were hub nodes (Figure [6](#mgg31126-fig-0006){ref-type="fig"}). These core nodes were all upregulated genes: Enhancer of zeste homolog 2 (*EZH2*, OMIM:601573), cell division cycle‐associated 1 (*CDCA1/NUF2*, OMIM:611772), PDZ binding kinase, *CDCA8(*OMIM:609977*)*, *CDCA7*(OMIM:609937), aurora kinase A (*AURKA*, OMIM:603072), replication factor C4 (*RFC4*, OMIM:102577), ubiquitin conjugating enzyme E2 C (*UBE2C*, OMIM:605574), centromere protein A (*CENPA*, OMIM:117139), targeting protein for xklp2 (*TPX2*, OMIM:605917), TTK protein kinase (*TTK*, OMIM:604092), V‐Myb avian myeloblastosis viral oncogene homolog‐like 2 (*MYBL2*, OMIM:601415), pituitary tumor transforming gene 1 (*PTTG1*, OMIM:604147), DNA topoisomerase II α (*TOP2A*, OMIM:126430), centromere protein U (*CENPU*, OMIM:611511), and *UBE2T*( OMIM:610538).

![Common DEGs PPI network constructed by STRING online database and Module analysis. (a) There were a total of 48 DEGs in the DEGs PPI network complex. (b) The most significant module in the PPI network of the DEGs Module analysis of Cytoscape software (degree cutoff = 2, node score cutoff = 0.2, k‐core = 2, and max. depth = 100). The nodes meant proteins; the edges meant the interaction of proteins; yellow nodes meant DEGs with high marks. DEGs, differentially expressed genes](MGG3-8-e1126-g006){#mgg31126-fig-0006}

3.4. Analysis of core genes by the Oncomine database {#mgg31126-sec-0019}
----------------------------------------------------

The Oncomine database (<http://www.oncomine.org>) was used to determine the expression patterns of 16 hub genes between normal and cancerous lung tissues. Due to the rarity of LCNEC, the expression pattern was only obtained in SCLC samples and compared with normal lung samples. The results showed that, except for TTK (deficiency in expression data), 14 of 15 genes were highly expressed in SCLC specimens, as compared with normal ones, which was consistent with the <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1037> data (Figure [7](#mgg31126-fig-0007){ref-type="fig"}).

![Significantly expressed 14 genes in SCLC tissues, as compared with normal tissues. SCLC, small cell lung carcinoma](MGG3-8-e1126-g007){#mgg31126-fig-0007}

3.5. Re‐analysis of hub genes by biological pathway analysis {#mgg31126-sec-0020}
------------------------------------------------------------

To better apprehend the pathway correlated with these 16 selected DEGs, biological pathway analysis was performed again by FunRich. The results showed that these 16 core genes were markedly enriched in the cell cycle pathway, mitotic prometaphase, DNA replication and M phase (Figure [8](#mgg31126-fig-0008){ref-type="fig"}). Among them the cell cycle pathway was the most markedly enriched, containing 10 genes (*CDCA1, CDCA8, AURKA, RFC4, UBE2C, CENPA, CENPU, MYBL2, PTTG1,* and *TOP2A*) (*p* = 2.30182e‐11).

![Re‐analysis of 16 hub genes by biological pathway enrichment. X axis represents significant biological pathway terms; Y axis represents percentage of genes or --log10 (*p*‐value)](MGG3-8-e1126-g008){#mgg31126-fig-0008}

3.6. Prediction of target miRNAs for hub genes {#mgg31126-sec-0021}
----------------------------------------------

The target human miRNAs for hub genes were determined by FunRich software, and the mRNA‐miRNA network was displayed by Cytoscape (Figure [9](#mgg31126-fig-0009){ref-type="fig"}). The genes found to be connected with miRNAs were *TTK, PTTG1, MYBL2, EZH2, CENPA, CDCA8, CDCA7,* and *AURKA*. Hub genes and their corresponded target miRNAs are presented in Table [3](#mgg31126-tbl-0003){ref-type="table"}. Finally, 31 miRNAs, whose functions were correlated with tumor progression (Chang et al., [2019](#mgg31126-bib-0011){ref-type="ref"}; Chang et al., [2017](#mgg31126-bib-0013){ref-type="ref"}; Chen et al., [2015](#mgg31126-bib-0014){ref-type="ref"}; Gao et al., [2018](#mgg31126-bib-0025){ref-type="ref"}; Gu et al., [2014](#mgg31126-bib-0030){ref-type="ref"}; Han et al., [2019](#mgg31126-bib-0034){ref-type="ref"}; He et al., [2019](#mgg31126-bib-0038){ref-type="ref"}; Kucuksayan et al., [2019](#mgg31126-bib-0051){ref-type="ref"}; Li, Ma, Zhang, Ji, & Jin, [2014](#mgg31126-bib-0057){ref-type="ref"}; Li, Ran, et al., [2018](#mgg31126-bib-0058){ref-type="ref"}; Li & He, [2014](#mgg31126-bib-0060){ref-type="ref"}; Li, Fu, et al., [2019](#mgg31126-bib-0061){ref-type="ref"}; Li, Cui, Li, Zhang, & Li, [2018](#mgg31126-bib-0062){ref-type="ref"}; Liu et al., [2017](#mgg31126-bib-0065){ref-type="ref"}; Liu, Liu, Deng, et al., [2019](#mgg31126-bib-0067){ref-type="ref"}; Liu, Liu, & Lu, [2019](#mgg31126-bib-0068){ref-type="ref"}; Liu, Liu, Zhang, Tong, & Gan, [2019](#mgg31126-bib-0070){ref-type="ref"}; Liu, Miao, et al., [2016](#mgg31126-bib-0071){ref-type="ref"}; Luo et al., [2018](#mgg31126-bib-0074){ref-type="ref"}; Tang et al., [2018](#mgg31126-bib-0101){ref-type="ref"}; Wang et al., [2017](#mgg31126-bib-0113){ref-type="ref"}; Wang, Cao, Su, Li, & Yan, [2019](#mgg31126-bib-0114){ref-type="ref"}; Wu et al., [2015](#mgg31126-bib-0120){ref-type="ref"}; Wu, Mo, Wan, Dan, & Hu, [2019](#mgg31126-bib-0121){ref-type="ref"}; Xia, Jing, Li, & Lv, [2018](#mgg31126-bib-0125){ref-type="ref"}; Xu et al., [2018](#mgg31126-bib-0128){ref-type="ref"}; Zeng et al., [2018](#mgg31126-bib-0131){ref-type="ref"}; Zhang, Hao, et al., [2018](#mgg31126-bib-0132){ref-type="ref"}; Zhang et al., [2014](#mgg31126-bib-0134){ref-type="ref"}, [2017](#mgg31126-bib-0137){ref-type="ref"}; Zhu et al., [2017](#mgg31126-bib-0139){ref-type="ref"}), drug resistance (Bian et al., [2019](#mgg31126-bib-0007){ref-type="ref"}; Gao et al., [2014](#mgg31126-bib-0026){ref-type="ref"}; Lin, Xie, Lu, Hu, & Chang, [2018](#mgg31126-bib-0064){ref-type="ref"}; Pan, Chen, Shen, & Tantai, [2019](#mgg31126-bib-0085){ref-type="ref"}; Su et al., [2016](#mgg31126-bib-0098){ref-type="ref"}; Xu et al., [2017](#mgg31126-bib-0129){ref-type="ref"}; Zhou, Wang, & Feng, [2014](#mgg31126-bib-0138){ref-type="ref"}), radiosensitivity (Liu, Li, & Gao, [2016](#mgg31126-bib-0066){ref-type="ref"}), recurrence (Sim et al., [2018](#mgg31126-bib-0094){ref-type="ref"}) or autophagy (Pan et al., [2019](#mgg31126-bib-0085){ref-type="ref"}) in lung cancer, were identified (Table [4](#mgg31126-tbl-0004){ref-type="table"}).

![Target gene‐miRNA networks of hub genes. Blue node stands for 8 hub genes, pink node stands for miRNA. The network was visualized by Cytoscape](MGG3-8-e1126-g009){#mgg31126-fig-0009}

###### 

Hub genes and corresponded target miRNAs

  Gene    miRNA
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TTK     hsa‐miR‐101‐3p hsa‐miR‐212‐3p hsa‐miR‐132‐3p hsa‐miR‐140‐5p hsa‐miR‐455‐3p hsa‐miR‐582‐5p
  PTTG1   hsa‐miR‐655‐3p hsa‐miR‐374c‐5p
  MYBL2   hsa‐miR‐29a‐3p hsa‐miR‐29b‐3p hsa‐miR‐30c‐5p hsa‐miR‐30a‐5p hsa‐miR‐30b‐5p hsa‐miR‐30d‐5p hsa‐miR‐29c‐3p hsa‐miR‐30e‐5p hsa‐miR‐423‐5p hsa‐miR‐3184‐5p
  EZH2    hsa‐miR‐101‐3p hsa‐miR‐124‐3p hsa‐miR‐137 hsa‐miR‐138‐5p
  CENPA   hsa‐miR‐873‐5p
  CDCA8   hsa‐let‐7a‐5p hsa‐let‐7b‐5p hsa‐let‐7c‐5p hsa‐let‐7d‐5p hsa‐let‐7e‐5p hsa‐let‐7f‐5p hsa‐miR‐98‐5p hsa‐let‐7g‐5p hsa‐let‐7i‐5p hsa‐miR‐133a‐3p hsa‐miR‐133b hsa‐miR‐4458 hsa‐miR‐4500
  CDCA7   hsa‐miR‐30a‐5p hsa‐miR‐30b‐5p hsa‐miR‐30c‐5p hsa‐miR‐30d‐5p hsa‐miR‐30e‐5p hsa‐miR‐302a‐3p hsa‐miR‐302‐3p hsa‐miR‐302c‐3p hsa‐miR‐302d‐3p hsa‐miR‐372‐3p hsa‐miR‐373‐3p hsa‐miR‐520e hsa‐miR‐520b hsa‐miR‐520f‐3p hsa‐miR‐520a‐3p hsa‐miR‐520d‐3p hsa‐miR‐520c‐3p hsa‐miR‐499a‐5p hsa‐miR‐302e
  AURKA   hsa‐miR‐25‐3p hsa‐miR‐92a‐3p hsa‐miR‐363‐3p hsa‐miR‐367‐3p hsa‐miR‐490‐3p hsa‐miR‐92b‐3p hsa‐miR‐421 hsa‐miR‐32‐5p
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###### 

Functions of miRNAs in lung cancer

  Gene    miRNA
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TTK     hsa‐miR‐101‐3p hsa‐miR‐212‐3p hsa‐miR‐132‐3p hsa‐miR‐140‐5p hsa‐miR‐455‐3p hsa‐miR‐582‐5p
  PTTG1   hsa‐miR‐655‐3p hsa‐miR‐374c‐5p
  MYBL2   hsa‐miR‐29a‐3p hsa‐miR‐29b‐3p hsa‐miR‐30c‐5p hsa‐miR‐30a‐5p hsa‐miR‐30b‐5p hsa‐miR‐30d‐5p hsa‐miR‐29c‐3p hsa‐miR‐30e‐5p hsa‐miR‐423‐5p hsa‐miR‐3184‐5p
  EZH2    hsa‐miR‐101‐3p hsa‐miR‐124‐3p hsa‐miR‐137 hsa‐miR‐138‐5p
  CENPA   hsa‐miR‐873‐5p
  CDCA8   hsa‐let‐7a‐5p hsa‐let‐7b‐5p hsa‐let‐7c‐5p hsa‐let‐7d‐5p hsa‐let‐7e‐5p hsa‐let‐7f‐5p hsa‐miR‐98‐5p hsa‐let‐7g‐5p hsa‐let‐7i‐5p hsa‐miR‐133a‐3p hsa‐miR‐133b hsa‐miR‐4458 hsa‐miR‐4500
  CDCA7   hsa‐miR‐30a‐5p hsa‐miR‐30b‐5p hsa‐miR‐30c‐5p hsa‐miR‐30d‐5p hsa‐miR‐30e‐5p hsa‐miR‐302a‐3p hsa‐miR‐302‐3p hsa‐miR‐302c‐3p hsa‐miR‐302d‐3p hsa‐miR‐372‐3p hsa‐miR‐373‐3p hsa‐miR‐520e hsa‐miR‐520b hsa‐miR‐520f‐3p hsa‐miR‐520a‐3p hsa‐miR‐520d‐3p hsa‐miR‐520c‐3p hsa‐miR‐499a‐5p hsa‐miR‐302e
  AURKA   hsa‐miR‐25‐3p hsa‐miR‐92a‐3p hsa‐miR‐363‐3p hsa‐miR‐367‐3p hsa‐miR‐490‐3p hsa‐miR‐92b‐3p hsa‐miR‐421 hsa‐miR‐32‐5p
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4. DISCUSSION {#mgg31126-sec-0022}
=============

To determine more possible targets for the exploration of SCLC and LCNEC biomarkers and molecular mechanisms, integrated bioinformatics methods based on the <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1037> profile dataset were performed in the present study. Eighteen primary normal lung tissues, 8 primary LCNEC tissues, 15 primary SCLC tissues, and 9 SCLC cell lines were enrolled and analyzed. Using GEO2R and Venn tools, 88 common DEGs were detected (\|logFC\| \> 2, adjusted *p* \< .05) in SCLC and LCNEC, including 32 up‐ (\|logFC \< 0) and 56 downregulated DEGs (\|logFC \< 0). Subsequently, functional enrichment and GO analysis were performed by DAVID, which showed the following: (a) For BP, the significantly enriched terms of up‐regulated DEGs were cell division, regulation of transcription, DNA repair, homologous chromosome segregation, positive regulation of exit from mitosis, mitotic nuclear division, glucose import, chromosome organization, protein K11‐linked ubiquitination, mitotic spindle organization and mitotic spindle assembly, and the significantly enriched terms of downregulated DEGs were caveola assembly, cell adhesion, receptor‐mediated endocytosis of virus by host cell, dopamine catabolic process, neurotransmitter catabolic process, multicellular organismal water homeostasis, angiogenesis, bleb assembly, ethanol oxidation, glycerol transport, and cellular water homeostasis; (b) for MF, the notably enriched terms of upregulated DEGs were ubiquitin protein ligase binding, DNA binding, ATP binding, peptidase inhibitor activity and ubiquitin conjugating enzyme activity, and those of downregulated DEGs were oxidoreductase, transporter, alcohol dehydrogenase (zinc‐dependent), water transmembrane transporter, primary amine oxidase, glycerol channel and water channel activities; (c) for CC, upregulated DEGs were particularly enriched in the cytoplasm, nucleus, axon hillock, chromosome passenger complex, nucleoplasm, pronucleus and spindle midzone, and down‐regulated DEGs in extracellular exosome, plasma membrane, caveola, extracellular region, membrane raft, apical part of cell, integral component of membrane, extracellular matrix, extracellular space and acrosomal membrane. To further explore the role of DEGs in biological pathways, the FunRich database was used. It was revealed that upregulated DEGs were notably enriched in the cell cycle pathway (mitotic), DNA replication, ATM pathway, mitotic M‐M/G1 phases, signaling by Aurora kinases, M phase, and mitotic prometaphase, while downregulated DEGs in lipid digestion, mobilization transport, noradrenaline and adrenaline degradation, and serotonin degradation. A PPI network complex of 48 nodes with 221 edges was then generated using STRING and Cytoscape. Next, 16 key upregulated genes were selected by MCODE analysis. Furthermore, following a re‐analysis of biological pathways by FunRich, 10 genes (*CDCA1, CDCA8, AURKA, RFC4, UBE2C, CENPA, CENPU, MYBL2, PTTG1,* and *TOP2A*) enriched in the cell cycle pathway were screened. In the meantime, target miRNAs associated with hub genes were predicted, and 8 genes (*TTK, PTTG1, MYBL2, EZH2, CENPA, CDCA8, CDCA7,* and *AURKA*) and 51 miRNAs involved in the mRNA‐miRNA regulatory network of SCLC and LCNEC were identified.

*CDCA1*, is a centromeric protein (Nabetani, Koujin, Tsutsumi, Haraguchi, & Hiraoka, [2001](#mgg31126-bib-0081){ref-type="ref"}), also known as *NUF2*. The gene has been reported to be co‐expressed with cell cycle‐related genes, including *CDC2*, cyclin, *TOP2A*, and others (Walker, [2001](#mgg31126-bib-0108){ref-type="ref"}), which was in line with the present results. It has been identified that the coactivation of *KNTC2* and *CDCA1* and their cognate interactions had an impact on pulmonary carcinogenesis, and that the inhibition of the *KNTC2‐CDCA1* complex would provide a novel strategy for therapy of lung cancer treatment. *CDCA1* was also regarded as a potential interacting protein for ZW10, a prognostic marker for lung cancer (Hayama et al., [2006](#mgg31126-bib-0036){ref-type="ref"}; Yuan et al., [2018](#mgg31126-bib-0130){ref-type="ref"}). In addition, *CDCA1* is projected to be a candidate of tumor‐associated antigens (TAA) in SCLC. *CDCA1*, with increasing levels in SCLC, could act as a TAA in inducing cytotoxic T lymphocytes (CTLs) which killed tumor cell lines, and therefore made differences in immunotherapy.(Harao et al., [2008](#mgg31126-bib-0035){ref-type="ref"}).

*CDCA8*, a member of the chromosomal passenger complex, is indispensable for the transmission of the genome in the process of cell division (Hindriksen, Meppelink, & Lens, [2015](#mgg31126-bib-0040){ref-type="ref"}). Bidkhori et al constructed a co‐expression network and identified *CDCA8* as a crucial gene in lung adenocarcinoma (Bidkhori et al., [2013](#mgg31126-bib-0009){ref-type="ref"}). Another study implied that the *CDCA8‐AURKB* pathway participated in the process of lung carcinogenesis (Hayama et al., [2007](#mgg31126-bib-0037){ref-type="ref"}). However, we failed to obtain studies of the impact of *CDCA8* neither in SCLC nor in LCNEC.

*AURKA*, a serine‐threonine protein kinase, was found to be involved in several crucial mitotic events and was regarded as an oncogene in multiple types of cancer (Vader & Lens, [2008](#mgg31126-bib-0104){ref-type="ref"}). In SCLC cell lines, a decreased level of *AURKA* inhibited cell proliferation and promoted apoptosis, and the inhibition of *AURKA* may be involved in the G2/M phase arrest of the cell cycle (Lu et al., [2014](#mgg31126-bib-0073){ref-type="ref"}). Apart from that way, *AURKA* was involved in immunotherapy in SCLC by being regarded as a TAA to induce CTLs.(Babiak et al., [2014](#mgg31126-bib-0005){ref-type="ref"}) Recently, more and more studies are concentrating on Aurora Kinase Inhibitors, PF‐03814735 and AZD1152, which establishes its pivotal status of SCLC in vitro and vivo.(Helfrich et al., [2016](#mgg31126-bib-0039){ref-type="ref"}; Hook et al., [2012](#mgg31126-bib-0041){ref-type="ref"}) Studies have also underlined the role of *AURKA* in platinum‐resistance as well as acquired resistance to third‐generation EGFR inhibitors (both osimertinib and rociletinib) (Gay et al., [2019](#mgg31126-bib-0028){ref-type="ref"}; Shah et al., [2019](#mgg31126-bib-0092){ref-type="ref"}). In addition, *AURKA* was reportedly correlated with poor prognosis in smoking‐related lung adenocarcinoma (Zhang, Hao, et al., [2018](#mgg31126-bib-0132){ref-type="ref"}).

*RFC4* is a member of the RFC family and has been found to be involved in DNA replication (Arai et al., [2009](#mgg31126-bib-0003){ref-type="ref"}). In colorectal cancer, the forced expression of *RFC4* was associated with tumor progression, poor prognosis (Xiang et al., [2014](#mgg31126-bib-0126){ref-type="ref"}), and radioresistance (X. C. Wang, Yue, et al., [2019](#mgg31126-bib-0116){ref-type="ref"}). *RFC4* knockdown in liver cancer cells could suppress proliferation and induce apoptosis (Arai et al., [2009](#mgg31126-bib-0003){ref-type="ref"}). In lung adenocarcinoma, *RFC4* was regulated by an oncogene, protein kinases C (*PKC*)‐iota, and correlated with the PKC‐iota expression in several more tumor types (Erdogan, Klee, Thompson, & Fields, [2009](#mgg31126-bib-0023){ref-type="ref"}).

*UBE2C*, a ubiquitin‐conjugating enzyme, works with the ubiquitin‐activating enzyme E1 and ubiquitin protein ligase E3 to degradate key regulatory molecules in cell cycle progression (Mayer, [2000](#mgg31126-bib-0077){ref-type="ref"}). In addition, *UBE2C* intervened in the cell cycle, apoptosis and transcription processes and controlled tumoriogenesis. Previous studies have implied that *UBE2C* promotes cell growth (Jin et al., [2019](#mgg31126-bib-0045){ref-type="ref"}; van Ree, Jeganathan, Malureanu, & van Deursen, [2010](#mgg31126-bib-0105){ref-type="ref"}; Sivakumar et al., [2017](#mgg31126-bib-0096){ref-type="ref"}) in NSCLC and is correlated with poor prognosis (Chen et al., [2011](#mgg31126-bib-0015){ref-type="ref"}; Guo et al., [2017](#mgg31126-bib-0033){ref-type="ref"}; Psyrri et al., [2012](#mgg31126-bib-0087){ref-type="ref"}). In addition, UBE2C participated in the miR 495‐*UBE2C*‐*ABCG2/ERCC1* axis regulating cisplatin resistance and mediating autophagy in NSCLC (Guo, Jin, et al., [2018](#mgg31126-bib-0031){ref-type="ref"}; Guo, Wu, et al., [2018](#mgg31126-bib-0032){ref-type="ref"}).*UBE2C* were in similarly high level in small‐cell prostate carcinoma (SCPC) and LCNEC of the prostate with xenografts, and the expression of *UBE2C* in SCLC and LCNEC of the lung might bear a strong resemblance to that of SCPC and LCNEC of the prostate (Tzelepi et al., [2012](#mgg31126-bib-0103){ref-type="ref"}).

*CENPA*, a centromere‐specific 17‐kDa protein, is a crucial histone H3 variant that acts as a vital epigenetic mark for the identity and propagation of the centromere (Allshire & Karpen, [2008](#mgg31126-bib-0001){ref-type="ref"}). *CENPA* played an essential role in cell cycle regulation and tumor cell survival (Takada et al., [2017](#mgg31126-bib-0100){ref-type="ref"}). Recent studies have identified the impacts of *CENPA* in lung cancer. Liu et al. ([2018](#mgg31126-bib-0069){ref-type="ref"}) used integrated microarray analysis and confirmed *CENPA*, cyclin‐dependent kinase 1, and cell‐division cycle protein 20 as a cluster of prognostic biomarkers for patients with lung adenocarcinoma. It has also been revealed that *CENPA* intensifies the aggressive phenotype of lung adenocarcinoma and is associated with patient prognosis (Cheng et al., [2019](#mgg31126-bib-0016){ref-type="ref"}; Wu et al., [2014](#mgg31126-bib-0122){ref-type="ref"}, [2012](#mgg31126-bib-0123){ref-type="ref"}).

*CENPU*, also known as *PBIP1/KLIP1/CENP‐50/MLF1IP*, is indispensable for kinetochore‐microtubule attachment, chromosome segregation, and recovery from spindle damage (Kagawa et al., [2014](#mgg31126-bib-0047){ref-type="ref"}; Walter et al., [2015](#mgg31126-bib-0109){ref-type="ref"}). Mounting evidence (Li, Zhang, Zhang, & Wang, [2018](#mgg31126-bib-0055){ref-type="ref"}; Wang et al., [2017](#mgg31126-bib-0113){ref-type="ref"}; Zhang et al., [2015](#mgg31126-bib-0133){ref-type="ref"}) has indicated that *CENPU* influences several types of cancer, such as bladder and ovarian cancer, and prostate carcinoma. Furthermore, *CENPU* predicted poor survival in patients with lung carcinoma and affected lung tumor growth (Li, Wang, Pang, Zhang, & Wang, [2019](#mgg31126-bib-0056){ref-type="ref"}; Wang et al., [2018](#mgg31126-bib-0115){ref-type="ref"}; Zhang, Li, Zhang, & Shi, [2018](#mgg31126-bib-0136){ref-type="ref"}).

*MYBL2* participated in cell cycle regulation, cell survival, and EMT‐associated processes in carcinoma (Musa, Aynaud, Mirabeau, Delattre, & Grunewald, [2017](#mgg31126-bib-0080){ref-type="ref"}). Accumulating evidence has indicated that *MYBL2* regulated tumorigenesis and cancer progression in multiple types of cancer. The high expression of *MYBL2* disrupted the DREAM complex and then hindered the cell cycle process in breast and ovarian cancer (Iness et al., [2019](#mgg31126-bib-0044){ref-type="ref"}). In liver cancer cells, YAP supported cell proliferation in an *MYBL2*‐dependant manner (Wei et al., [2019](#mgg31126-bib-0118){ref-type="ref"}). In addition, Fan et al. ([2018](#mgg31126-bib-0024){ref-type="ref"}) and Jin et al. ([2017](#mgg31126-bib-0046){ref-type="ref"}) stressed the oncogenic impacts of *MYBL2* and its capacity to serve as a therapeutic target in NSCLC. Moreover the overexpression of *MYBL2* was found to be related to that of the ubiquitin carboxyterminal hydrolase UCHL1 (an enzyme expressed in neurons and neuroendocrine cells in the lung) in murine, because of the reciprocal action of the UCHL1 enzyme and *MYBL2* (Long, Long, Tsirigotis, & Gray, [2003](#mgg31126-bib-0072){ref-type="ref"}).

*PTTG1* is a novel proto‐oncogene that is overexpressed in different types of human cancers, including endocrine‐ and nonendocrine‐related types (Vlotides, Eigler, & Melmed, [2007](#mgg31126-bib-0106){ref-type="ref"}). Wu, Zhang, et al. ([2019](#mgg31126-bib-0124){ref-type="ref"})) revealed the importance of *PTTG1* as a potential biomarker in NSCLC. Accordingly, Wang, Liu, and Chen ([2016](#mgg31126-bib-0110){ref-type="ref"}) emphasized the prognostic value of *PTTG1* in lung cancer, showing the level of PGGT1 as an optimal parameter to predict malignant status and prognosis in NSCLC patients.

*TOP2A* is a type of isozyme type II topoisomerases (Li & Liu, [2001](#mgg31126-bib-0059){ref-type="ref"}). A dysregulated *TOP2A* has been observed in multiple types of cancer and been used in the treatment of several carcinomas (Lan et al., [2014](#mgg31126-bib-0054){ref-type="ref"}; Li et al., [2015](#mgg31126-bib-0063){ref-type="ref"}; Wesierska‐Gadek & Skladanowski, [2012](#mgg31126-bib-0119){ref-type="ref"}). *TOP2A* has been shown to be involved not only in NSCLC (Chien et al., [2019](#mgg31126-bib-0018){ref-type="ref"}; Olaussen & Postel‐Vinay, [2016](#mgg31126-bib-0084){ref-type="ref"}), but also in SCLC (Chiappori et al., [2010](#mgg31126-bib-0017){ref-type="ref"}). Chiappori et al. ([2010](#mgg31126-bib-0017){ref-type="ref"}) recommended *TOP2A* as a biomarker of chemotherapeutic efficacy in SCLC. Chang et al. ([2017](#mgg31126-bib-0013){ref-type="ref"})) and Gray et al. ([2017](#mgg31126-bib-0029){ref-type="ref"}) considered *TOP2A* as a target of anti‐small cell lung cancer agents. Furthermore, in silico analyses showed *TOP2A* as target gene of miR‐27a‐5p and miR‐34b‐3p, both of whom were tumor suppressors in SCLC (Mizuno et al., [2017](#mgg31126-bib-0079){ref-type="ref"}). A current research showed that compared with lung adenocarcinoma, *TOP2A* was a potential drug target of the therapy in LCNEC due to its overexpression examined by immunohistochemistry (Makino et al., [2016](#mgg31126-bib-0075){ref-type="ref"}). Although *TOP2A* was highly expressed in NENs, no evident difference in expression levels was found between SCLC and LCNEC (Neubauer et al., [2016](#mgg31126-bib-0083){ref-type="ref"}).

The results of re‐analysis of biological pathway revealed that most key genes were enriched in cell cycle (mitotic), mitotic prometaphase, DNA replication, and M phase. Accordingly, because of the high genome instability as a result of high level replication stress in SCLC, the inhibition of DNA‐replication stress‐response, especially in combination with cisplatin, was one of the vulnerabilities of SCLC, which provided a novel therapy for this type of cancer (Bian & Lin, [2019](#mgg31126-bib-0008){ref-type="ref"}; Nagel et al., [2019](#mgg31126-bib-0082){ref-type="ref"}). Prometaphase arrest caused by mitotic spindle formation defects that resulting from the depletion of Aurora A, was also involved with the inhibition of cell growth in SCLC (Du et al., [2019](#mgg31126-bib-0022){ref-type="ref"}). Additionally, the inhibition of a pivotal mitotic regulator led to the increase in the population of cells in the G2/M phase (Wang et al., [2018](#mgg31126-bib-0115){ref-type="ref"}), while treatment with etoposide in TP53 gene abnormalities ones resulted in the lack of G1/S arrest (Soues, Wiltshire, & Smith, [2001](#mgg31126-bib-0097){ref-type="ref"}), all of which were associated with pathways of mitotic cell cycle or M phase in SCLC cell lines.

To sum up, *CDCA1* and *AURK4* might be characteristic especially to SCLC, while *MYBL2* is the biomarker of LCNEC. The biological pathway of DNA replication, mitotic cell cycle, mitotic prometaphase, and M phase might be characteristic to SCLC. In contrast, no evidence has been shown that any pathway enrichment is related to LCNEC, and the genes of *CDCA8*, *RFC4*, *UBE2C*, *CENPA*, *CENPU*, *PTTG1,* and *TOP2A* are not predicted to participate particularly in SCLC or LCNEC. Although further researches should be performed focusing on more functions of these key genes and pathways, our discoveries provide potential candidates useful for the diagnosis and discrimination between SCLC and LCNEC.

miRNAs play essential roles in the genesis, development, and progression of carcinoma (Rupaimoole & Slack, [2017](#mgg31126-bib-0090){ref-type="ref"}). Aberrant miRNA expression profiles have been identified in multiple subtypes of lung cancer (Lai et al., [2019](#mgg31126-bib-0053){ref-type="ref"}; Mao et al., [2019](#mgg31126-bib-0076){ref-type="ref"}; Wang et al., [2018](#mgg31126-bib-0115){ref-type="ref"}). In addition to DEGs and their functions, miRNAs can influence multiple processes of lung cancer, including drug resistance, tumor progression and recurrence, autophagy and radio‐sensitivity. The role of miRNAs in tumor growth is shown in Table [4](#mgg31126-tbl-0004){ref-type="table"}. Recent studies have also revealed the impacts of miRNAs, including miR‐363‐3p, miR‐30a‐5p, miR‐133b, miR‐98‐5p, miR‐138‐5p, miR‐137, and miR‐138‐5p, on drug resistance in NSCLC, showing that miRNAs participated in the mechanisms of traditional chemotherapeutic drugs \[gemcitabine (Bian et al., [2019](#mgg31126-bib-0007){ref-type="ref"}), paclitaxel (Xu et al., [2017](#mgg31126-bib-0129){ref-type="ref"}), and cisplatin (Lin et al., [2018](#mgg31126-bib-0064){ref-type="ref"}; Pan et al., [2019](#mgg31126-bib-0085){ref-type="ref"}; Su et al., [2016](#mgg31126-bib-0098){ref-type="ref"}; Zhou et al., [2014](#mgg31126-bib-0138){ref-type="ref"})\] as well as targeted drugs \[gefitinib (Gao et al., [2014](#mgg31126-bib-0026){ref-type="ref"})\]. In addition, Sim et al demonstrated that let‐7g‐5p was associated with recurrence in stage I lung adenocarcinoma (Sim et al., [2018](#mgg31126-bib-0094){ref-type="ref"}). Other studies also elucidated the roles of miRNAs in autophagy and radio‐sensitivity (Liu, Miao, et al., [2016](#mgg31126-bib-0071){ref-type="ref"}; Pan et al., [2019](#mgg31126-bib-0085){ref-type="ref"}).

However, the present study had several limitations. First, due to the rarity of LCNEC and SCLC, we failed to provide meaningful prognosis information from public databases. Second, the present data were obtained from the GEO database, so the reliability and quality of the statistics cannot be evaluated. Third, this study lacks more convincing evidence, such as qPCR and immunohistochemistry results.

5. CONCLUSIONS {#mgg31126-sec-0023}
==============

In conclusion, common DEGs of SCLC and LCNEC were identified by integrated bioinformatics methods and 16 hub genes were selected from PPI network, among which 10 genes were shown to be related to the most significantly enriched pathway, cell cycle pathway. The roles of these genes and pathways in lung cancer were further discussed and the application of these genes in treatment of SCLC and LCNEC is worthy of further study. In addition, the functions in lung cancer of miRNAs corresponding to 16 core genes were discussed. Several studies have tried to explore novel strategies (Christopoulos et al., [2017](#mgg31126-bib-0019){ref-type="ref"}; Kujtan et al., [2018](#mgg31126-bib-0052){ref-type="ref"}; Saunders et al., [2015](#mgg31126-bib-0091){ref-type="ref"}) for the treatment of SCLC and LCNEC. Attempts at identifying the values of molecular targets, such as spread through air spaces, and immune therapy, such as the expression of PD‐L1 and mutation burden, are ongoing (Aly et al., [2019](#mgg31126-bib-0002){ref-type="ref"}; Kim et al., [2018](#mgg31126-bib-0050){ref-type="ref"}). To determine the various roles of emerging molecules in the process of tumorigenesis and progression of SCLC and LCNEC, further research should be conducted.
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